Why CAR-T Therapies Don’t Work for Everyone Yet – Genetic Engineering & Biotechnology News
|
Why CAR–T Therapies Don't Work for Everyone Yet
Genetic Engineering & Biotechnology News The newest treatment categorized as a living drug is called Kymriah (tisagenlecleucel). Developed by Novartis, it is the first FDA-approved chimeric antigen receptor T–cell (CAR-T) therapy, which has helped patients battle against a blood cancer called … |
